Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719657 | 0.79 | TSHR (0.41) | FASNCYP3A4DAO | |
| SCHEMBL28661302 | 0.76 | FASN (0.37) | FASNSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6336780 | 0.75 | LMNA (0.49) | DAO | |
| SCHEMBL7081405 | 0.71 | CYP3A4 (0.54) | FASNCYP3A4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7081400 | 0.71 | CYP3A4 (0.54) | FASNCYP3A4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11138811 | 0.71 | FASN (0.58) | FASNCYP3A4PLA2G6PLA2G4ASLC6A2 | |
| SCHEMBL7990706 | 0.71 | — | — | |
| SCHEMBL4501425 | 0.69 | CYP3A4 (0.48) | FASNCYP3A4PLA2G6PLA2G4ADAO | |
| SCHEMBL9993726 | 0.68 | PDCD4 (0.38) | — | |
| SCHEMBL2600461 | 0.68 | CA12 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5541221-A | Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss | ALLERGAN (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0637240-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3 AND 4-SUBSTITUTED 2(5H)-FURANONES FOR INHIBITING BONE LOSS | ALLERGAN, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| US-5387606-A | Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss | ALLERGAN, INC. (US) | 1995-02-07 | — | — | US | disclosed |
| US-5268387-A | Containing ester or carbamate group | ALLERGAN, INC. (US) | 1993-12-07 | — | — | US | disclosed |
| WO-1993021915-A1 | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING BONE LOSS CONTAINING 3 AND 4-SUBSTITUTED 2(5H)-FURANONES | ALLERGAN, INC. (US) | 1993-11-11 | — | — | WO | disclosed |
| WO-1991016055-A1 | 2(5H)-FURANONES SUBSTITUTED IN THE 5 AND OR IN THE 4 POSITION, AS ANTI-INFLAMMATORY AGENTS | ALLERGAN, INC. (US) | 1991-10-31 | — | — | WO | disclosed |